LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
Background Randomized controlled trials (RCTs) indicate that long-acting bronchodilator
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …
Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta …
Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised …
JM Hohlfeld, J Vogel-Claussen, H Biller… - The Lancet …, 2018 - thelancet.com
Background Pulmonary hyperinflation in chronic obstructive pulmonary disease (COPD) is
associated with reduced biventricular end-diastolic volumes and increased morbidity and …
associated with reduced biventricular end-diastolic volumes and increased morbidity and …
Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD–2019 update of evidence
In this guideline update, we highlight important and new findings related to pharmacological
therapy of chronic obstructive pulmonary disease (COPD) that should change clinical …
therapy of chronic obstructive pulmonary disease (COPD) that should change clinical …
Fixed-intensity exercise tests to measure exertional dyspnoea in chronic heart and lung populations: a systematic review
Introduction Exertional dyspnoea is the primary diagnostic symptom for chronic
cardiopulmonary disease populations. Whilst a number of exercise tests are used, there …
cardiopulmonary disease populations. Whilst a number of exercise tests are used, there …
Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease
HA Farne, CJ Cates - Cochrane database of systematic …, 2015 - cochranelibrary.com
Background Long‐acting bronchodilators, comprising long‐acting beta 2‐agonists (LABA)
and long‐acting anti‐muscarinic agents (LAMA, principally tiotropium), are commonly used …
and long‐acting anti‐muscarinic agents (LAMA, principally tiotropium), are commonly used …
[HTML][HTML] Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD
Background Long-acting muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA)
combinations are a treatment option for patients with COPD who continue to have symptoms …
combinations are a treatment option for patients with COPD who continue to have symptoms …
[HTML][HTML] The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease
KM Beeh, J Westerman, AM Kirsten, J Hébert… - Pulmonary …, 2015 - Elsevier
Background This study investigated the effects on 24-h lung function and lung volume of a
once-daily fixed-dose combination (FDC) of the long-acting muscarinic antagonist tiotropium …
once-daily fixed-dose combination (FDC) of the long-acting muscarinic antagonist tiotropium …
[HTML][HTML] Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD
A Rossi, Z Aisanov, S Avdeev, G Di Maria… - Respiratory …, 2015 - Elsevier
The main complaint of patients with chronic obstructive pulmonary disease (COPD) is
shortness of breath with exercise, that is usually progressive. The principal mechanism that …
shortness of breath with exercise, that is usually progressive. The principal mechanism that …
Recent advances in dyspnea
DA Mahler, DE O'Donnell - Chest, 2015 - Elsevier
Dyspnea is the most prevalent symptom among patients with cardiac and respiratory
diseases. It is an independent predictor of mortality in patients with heart disease, COPD …
diseases. It is an independent predictor of mortality in patients with heart disease, COPD …